Clinical Trials Logo

Clinical Trial Summary

The Up-LIFT Study is a prospective, single-arm study designed to evaluate the safety and effectiveness of non-invasive electrical spinal cord stimulation (ARC Therapy) administered by the LIFT System to treat upper extremity functional deficits in people with chronic tetraplegia.


Clinical Trial Description

The primary endpoint of this pivotal study will report device related safety and changes in established metrics of upper extremity performance after treatment with the study device. To ensure that the benefits realized in the study are directly attributable to the ARC Therapy, all enrolled subjects will first undergo a guided, in-clinic conventional functional task practice (FTP) program lasting approximately two months to regain their upper extremity (UE) function. Performance gains realized during this wash-in period provide a subject specific control that reflects the limits of conventional functional task practice without stimulation (standard of care). At the conclusion of the wash-in period, subjects will complete pre-stimulation testing of UE function. To test the additive benefit of training with stimulation, combined functional task practice and ARC Therapy will then be administered over a period of approximately two months using the LIFT System. Functional task practice will follow established rehabilitation protocols that are specific to the individual subject's specific needs and capabilities (Beekhuizen & Field-Fote, Functional Task Practice versus Functional Task Practice with Stimulation: Effects on Upper Extremity Function and Cortical Plasticity in Individuals with Incomplete Cervical Spinal Cord Injury, 2005). Training will be graded to accommodate performance improvement over time, thus maximizing the potential benefit to subjects. Subjects will participate in up to 20 in-clinic training sessions per month. At the end of training period, the improvement in UE function will be measured and used to assess the progress of primary study endpoints. The choice of primary outcome measures for this pivotal study is dictated by the following factors - 1. Safety, 2. Relevance to UE function, 3. Capture improvements in performance, and 4. Magnitude of changes that are clinically meaningful. All performance metrics will be assessed at enrollment, at the completion of the wash-in period and at the end of the ARC Therapy assessment period. Subjects with clinically meaningful gains in multiple performance domains resulting from the ARC Therapy with LIFT will be considered responders. Additionally, gains during the wash-in (control) period will be compared to gains during the ARC Therapy with LIFT (test) period. Safety will be evaluated throughout the entire study through periodic monitoring and analysis of all reported adverse events. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04697472
Study type Interventional
Source ONWARD Medical, Inc.
Contact
Status Completed
Phase N/A
Start date January 8, 2021
Completion date September 13, 2022

See also
  Status Clinical Trial Phase
Completed NCT04074616 - Reducing Anticholinergic Bladder Medication Use in Spinal Cord Injury With Home Neuromodulation N/A
Completed NCT00816803 - Cell Transplant in Spinal Cord Injury Patients Phase 1/Phase 2
Completed NCT05284201 - LIFT Home Study of Non-Invasive ARC Therapy for Spinal Cord Injury N/A
Completed NCT03458871 - Home Neuromodulation of the Neurogenic Bladder in Chronic Spinal Cord Injury With Transcutaneous Tibial Nerve Stimulation N/A
Active, not recruiting NCT02136823 - Impact of Persistent Conductances on Motor Unit Firing in SCI N/A
Completed NCT03989440 - AXER-204 in Participants With Chronic Spinal Cord Injury Phase 1/Phase 2
Recruiting NCT05644171 - RESTORES Trial: RESToration Of Rehabilitative Function With Epidural Spinal Stimulation N/A
Recruiting NCT05965700 - NVG-291 in Spinal Cord Injury Subjects Phase 1/Phase 2